Cancer Care Centre Research Program is located at St George & Sutherland Clinical Campuses in Kogarah, NSW. Our program brings together interdisciplinary expertise in cell & molecular biology, extracellular vesicle, multi-omics, radiation oncology, urological oncology, novel imaging modalities and clinical trials, to improve outcomes for cancer patients.
Our goals
We advance patient-centred and clinically driven research to better understand how cancer starts, develops and spreads and to improve the diagnosis and treatment of prostate, breast and bladder cancers.Ìý
- Multi-omics biomarkers – discover transcriptomic, proteomic, lipidomic, metabolomic & microbiome signatures for personalised risk prediction, diagnosis and surveillance.
- Liquid biopsy – identify extracellular vesicle biomarkers for minimally invasive cancer detection and monitoring.
- Therapeutic resistance – unravel tumour-immune microenvironment drivers to guide new combination therapies.
- Innovative imaging – create next-generation modalities for early detection and risk stratification in urological cancers.
Research strengths
- Collaborative and multidisciplinary research team allowing for direct translation of knowledge.Ìý
- Direct access to specialist public and private clinics for patients with various cancer types.Ìý
- Cutting-edge next generation multi-omics approaches and liquid biopsy analysis platforms.Ìý
- Strong connections with community, industry partners and collaborators domestically and internationally.Ìý
- Extensive experience in clinical research including complex research ethics and randomised controlled trials. Ìý
Our results
- High-impact research output (>350 publications with >15,000 citations, team combined)Ìý
- Consistent grant funding success from USDOD, NHMRC, ARC, CINSW, TROG, Ovarian Cancer Foundation, Pancreatic Cancer Foundation, PBCF, ANZUP and SSMRF.ÌýÌý
- Successful supervision of >30 PhD, Masters and Honours students to completion.Ìý
- Paradigm-shifting research outcomes, including the first RCT on the use of boost radiation in DCIS patients (Lancet); PSMA-PET/CT+MRI trial for clinically significant prostate cancer diagnosis (European Urology); the world-first landmark MRI trial for prostate cancer active surveillance (The Journal of Urology), and the establishment of a novel liquid biopsy platform using blood exosome miRNA for prostate cancer risk stratification.Ìý
